Forest Laboratories, Inc. has signed a definitive merger agreement to acquire Cerexa, Inc. for $480 million cash. As part of the acquisition, Forest will obtain worldwide development and marketing rights (excluding Japan) to two injectable antibiotics and an option to a third, early stage injectable antibiotic. The lead compound, ceftaroline acetate, which is entering Phase III studies, is a next generation, broad-spectrum, hospital-based cephalosporin antibiotic that is being developed for init...